![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
The item has been added to your shopping cart.
Home » UCB AND SANOFI-AVENTIS SIGN A CO-PROMOTION AGREEMENT FOR XYZAL IN THE UNITED STATES
UCB AND SANOFI-AVENTIS SIGN A CO-PROMOTION AGREEMENT FOR XYZAL IN THE UNITED STATES
UCB and sanofi-aventis announced that they have entered into an agreement to co-promote in the United States the prescription antihistamine medicine, Xyzal (levocetirizine dihydrochloride). Xyzal is a once-daily antihistamine which was first launched in Europe in 2001 and currently marketed in 49 countries around the world where it enjoys leadership position in key markets.
Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=166345)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct